ArticleBrain & spine2026
Incidence and impact of intracranial complications in patients undergoing extracorporeal membrane oxygenation treatment.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracorporeal membrane oxygenation (ECMO) is a life-saving intervention for respiratory and/or cardiac failure but is associated with high morbidity and mortality, particularly due to intracranial complications. Research question: What is the incidence, type, and impact of intracranial complications in patients undergoing ECMO treatment? Material and methods: This retrospective single-center study included ECMO patients treated at a tertiary care center between 2013 and 2023. Patients with documented intracranial hemorrhage, cerebral ischemic stroke, or diffuse hypoxic cerebral edema were included. Demographic, clinical, radiological, and outcome data were analyzed. Results: Among 775 ECMO patients, 141 (18%) developed intracranial complications, including intracerebral hemorrhage (36%), subarachnoid hemorrhage (22%), diffuse hypoxic cerebral edema (25%), ischemic stroke (14%), and subdural hematoma (4%). Secondary deterioration (p = 0.009), midline shift (p = 0.005), and pupillary abnormalities (p < 0.001), were associated with in-hospital mortality, though only pupillary abnormalities remained significant in multivariate analysis (p = 0.006). Patients with diffuse hypoxic cerebral edema were younger (p < 0.001), had lower multimorbidity (p = 0.019, p < 0.001) and disease burden (p = 0.02, p = 0.011), and showed less secondary deterioration (p < 0.001) than those with bleeding or ischemic stroke. In-hospital mortality was higher in patients with intracranial complications (77%) compared to those without (59%, p < 0.001). Most survivors revealed severe disability, with a median modified Rankin Scale score of 5 at discharge. Discussion and conclusion: Acute intracranial complications in patients undergoing ECMO are frequent, heterogeneous in presentation, and associated with poor outcomes. Pupillary abnormalities emerged as the strongest predictor of mortality. Early identification of high-risk patients may facilitate targeted monitoring and timely interventions to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.